Sulfotransferase signaling sustains fibroblast identity and antagonizes therapeutic cardiac reprogramming.

Authors

Michaela R Romero, Sean Murphy, Yu-Ling Chang, Aashna Lamba, Sara Ancel, Alicia Llorente, James Marchant, Chun-Teng Huang, Caroline Kumsta, Peter Andersen, Sanjeev Ranade, Ahmed I Mahmoud, Chulan Kwon, Hudson H Freeze, Peter D Adams, Alessandra Sacco, Mark J Ranek, Brooke M Emerling, Yu Xin Wang, Alexandre R Colas

Published in

Nature communications. Jul 17, 2026. Epub Jul 17, 2026.

Abstract

Differentiated cells maintain their identity through active mechanisms that suppress alternative cell fates, but disrupting these barriers can enhance direct reprogramming for organ repair. Among the regulators of cell fate stability, glycosylation-associated genes have emerged as barriers to cardiac reprogramming. Here we show that carbohydrate sulfotransferases are central fate-stabilizing regulators, with CHST7 acting through CD44 to control nuclear JUNB levels, chromatin binding, and downstream transcriptional activity. Integrated RNA-seq and ATAC-seq analyses reveal that CHST7 maintains open chromatin at JUNB- and CTCF-enriched loci while restricting accessibility at MEF2C-enriched regions, collectively reinforcing fibroblast identity and suppressing cardiac fate acquisition. We further identify PIP4K2C as a downstream effector whose inhibition enhances cardiac reprogramming efficiency and improves myocardial repair in vivo. These findings define a sulfotransferase-dependent barrier to cell fate conversion with therapeutic implications for heart regeneration.

PMID:
42469251
Bibliographic data and abstract were imported from PubMed on 18 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.